Clinical standards for the dosing and management of TB drugs

J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori

doi:10.5588/ijtld.22.0188

Clinical standards for the dosing and management of TB drugs

J W C Alffenaar, S L Stocker, L Davies Forsman, A Garcia-Prats, S K Heysell, R E Aarnoutse, O W Akkerman, A Aleksa, R van Altena, W Arrazola de Oñata, P K Bhavani, N Van't Boveneind-Vrubleuskaya, A C C Carvalho, R Centis, J M Chakaya, D M Cirillo, J G Cho, L D Ambrosio, M P Dalcolmo, P DentiK Dheda, G J Fox, A C Hesseling, H Y Kim, C U Köser, B J Marais, I Margineanu, A G Märtson, M Munoz Torrico, H M Nataprawira, C W M Ong, R Otto-Knapp, C A Peloquin, D R Silva, R Ruslami, P Santoso, R M Savic, R Singla, E M Svensson, A Skrahina, D van Soolingen, S Srivastava, M Tadolini, S Tiberi, T A Thomas, Z F Udwadia, D H Vu, W Zhang, S G Mpagama, T Schön, G B Migliori

Microbes in Health and Disease (MHD)

Research output: Contribution to journal › Article › Academic › peer-review

54 Citations (Scopus)

133 Downloads (Pure)

Abstract

BACKGROUND: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on 'best practice´ for dosing and management of TB drugs.METHODS: A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants.RESULTS: Six clinical standards were defined: Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified.CONCLUSION: This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.

Original language	English
Pages (from-to)	483-499
Number of pages	17
Journal	International Journal of Tuberculosis and Lung Disease
Volume	26
Issue number	6
DOIs	https://doi.org/10.5588/ijtld.22.0188
Publication status	Published - 1-Jun-2022

Keywords

Drug Monitoring
Health Personnel
Humans
Patient Care
Reference Standards

Access to Document

10.5588/ijtld.22.0188Licence: CC BY

Clinical standards for the dosing and management of TB drugsFinal publisher's version, 473 KBLicence: CC BY

Handle.net

Persistent link

Cite this

Alffenaar, J. W. C., Stocker, S. L., Forsman, L. D., Garcia-Prats, A., Heysell, S. K., Aarnoutse, R. E., Akkerman, O. W., Aleksa, A., van Altena, R., de Oñata, W. A., Bhavani, P. K., Van't Boveneind-Vrubleuskaya, N., Carvalho, A. C. C., Centis, R., Chakaya, J. M., Cirillo, D. M., Cho, J. G., D Ambrosio, L., Dalcolmo, M. P., ... Migliori, G. B. (2022). Clinical standards for the dosing and management of TB drugs. International Journal of Tuberculosis and Lung Disease, 26(6), 483-499. https://doi.org/10.5588/ijtld.22.0188

@article{5c404b2ecde843e692a1c43877d8091f,

title = "Clinical standards for the dosing and management of TB drugs",

abstract = "BACKGROUND: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on 'best practice´ for dosing and management of TB drugs.METHODS: A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants.RESULTS: Six clinical standards were defined: Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified.CONCLUSION: This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.",

keywords = "Drug Monitoring, Health Personnel, Humans, Patient Care, Reference Standards",

author = "Alffenaar, {J W C} and Stocker, {S L} and Forsman, {L Davies} and A Garcia-Prats and Heysell, {S K} and Aarnoutse, {R E} and Akkerman, {O W} and A Aleksa and {van Altena}, R and {de O{\~n}ata}, {W Arrazola} and Bhavani, {P K} and {Van't Boveneind-Vrubleuskaya}, N and Carvalho, {A C C} and R Centis and Chakaya, {J M} and Cirillo, {D M} and Cho, {J G} and {D Ambrosio}, L and Dalcolmo, {M P} and P Denti and K Dheda and Fox, {G J} and Hesseling, {A C} and Kim, {H Y} and K{\"o}ser, {C U} and Marais, {B J} and I Margineanu and M{\"a}rtson, {A G} and Torrico, {M Munoz} and Nataprawira, {H M} and Ong, {C W M} and R Otto-Knapp and Peloquin, {C A} and Silva, {D R} and R Ruslami and P Santoso and Savic, {R M} and R Singla and Svensson, {E M} and A Skrahina and {van Soolingen}, D and S Srivastava and M Tadolini and S Tiberi and Thomas, {T A} and Udwadia, {Z F} and Vu, {D H} and W Zhang and Mpagama, {S G} and T Sch{\"o}n and Migliori, {G B}",

year = "2022",

month = jun,

day = "1",

doi = "10.5588/ijtld.22.0188",

language = "English",

volume = "26",

pages = "483--499",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union against Tubercul. and Lung Dis.",

number = "6",

}

Alffenaar, JWC, Stocker, SL, Forsman, LD, Garcia-Prats, A, Heysell, SK, Aarnoutse, RE, Akkerman, OW, Aleksa, A, van Altena, R, de Oñata, WA, Bhavani, PK, Van't Boveneind-Vrubleuskaya, N, Carvalho, ACC, Centis, R, Chakaya, JM, Cirillo, DM, Cho, JG, D Ambrosio, L, Dalcolmo, MP, Denti, P, Dheda, K, Fox, GJ, Hesseling, AC, Kim, HY, Köser, CU, Marais, BJ, Margineanu, I, Märtson, AG, Torrico, MM, Nataprawira, HM, Ong, CWM, Otto-Knapp, R, Peloquin, CA, Silva, DR, Ruslami, R, Santoso, P, Savic, RM, Singla, R, Svensson, EM, Skrahina, A, van Soolingen, D, Srivastava, S, Tadolini, M, Tiberi, S, Thomas, TA, Udwadia, ZF, Vu, DH, Zhang, W, Mpagama, SG, Schön, T & Migliori, GB 2022, 'Clinical standards for the dosing and management of TB drugs', International Journal of Tuberculosis and Lung Disease, vol. 26, no. 6, pp. 483-499. https://doi.org/10.5588/ijtld.22.0188

TY - JOUR

T1 - Clinical standards for the dosing and management of TB drugs

AU - Alffenaar, J W C

AU - Stocker, S L

AU - Forsman, L Davies

AU - Garcia-Prats, A

AU - Heysell, S K

AU - Aarnoutse, R E

AU - Akkerman, O W

AU - Aleksa, A

AU - van Altena, R

AU - de Oñata, W Arrazola

AU - Bhavani, P K

AU - Van't Boveneind-Vrubleuskaya, N

AU - Carvalho, A C C

AU - Centis, R

AU - Chakaya, J M

AU - Cirillo, D M

AU - Cho, J G

AU - D Ambrosio, L

AU - Dalcolmo, M P

AU - Denti, P

AU - Dheda, K

AU - Fox, G J

AU - Hesseling, A C

AU - Kim, H Y

AU - Köser, C U

AU - Marais, B J

AU - Margineanu, I

AU - Märtson, A G

AU - Torrico, M Munoz

AU - Nataprawira, H M

AU - Ong, C W M

AU - Otto-Knapp, R

AU - Peloquin, C A

AU - Silva, D R

AU - Ruslami, R

AU - Santoso, P

AU - Savic, R M

AU - Singla, R

AU - Svensson, E M

AU - Skrahina, A

AU - van Soolingen, D

AU - Srivastava, S

AU - Tadolini, M

AU - Tiberi, S

AU - Thomas, T A

AU - Udwadia, Z F

AU - Vu, D H

AU - Zhang, W

AU - Mpagama, S G

AU - Schön, T

AU - Migliori, G B

PY - 2022/6/1

Y1 - 2022/6/1

N2 - BACKGROUND: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on 'best practice´ for dosing and management of TB drugs.METHODS: A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants.RESULTS: Six clinical standards were defined: Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified.CONCLUSION: This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.

AB - BACKGROUND: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on 'best practice´ for dosing and management of TB drugs.METHODS: A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants.RESULTS: Six clinical standards were defined: Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified.CONCLUSION: This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.

KW - Drug Monitoring

KW - Health Personnel

KW - Humans

KW - Patient Care

KW - Reference Standards

U2 - 10.5588/ijtld.22.0188

DO - 10.5588/ijtld.22.0188

M3 - Article

C2 - 35650702

SN - 1027-3719

VL - 26

SP - 483

EP - 499

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 6

ER -

Clinical standards for the dosing and management of TB drugs

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this